ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 156 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2015. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $751,000 | -9.7% | 59,959 | -0.2% | 0.00% | 0.0% |
| Q3 2016 | $832,000 | +39.8% | 60,094 | -0.2% | 0.00% | 0.0% |
| Q2 2016 | $595,000 | -22.1% | 60,234 | +33.3% | 0.00% | 0.0% |
| Q1 2016 | $764,000 | -22.3% | 45,178 | +2.3% | 0.00% | 0.0% |
| Q4 2015 | $983,000 | -5.0% | 44,173 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $1,035,000 | -71.6% | 43,888 | -1.5% | 0.00% | -80.0% |
| Q2 2015 | $3,644,000 | +102.1% | 44,571 | +128.9% | 0.01% | +150.0% |
| Q1 2015 | $1,803,000 | +160.5% | 19,468 | +13.8% | 0.00% | +100.0% |
| Q4 2014 | $692,000 | +112.3% | 17,106 | +28.4% | 0.00% | – |
| Q3 2014 | $326,000 | +53.1% | 13,323 | -0.9% | 0.00% | – |
| Q2 2014 | $213,000 | +5.4% | 13,447 | +0.5% | 0.00% | – |
| Q1 2014 | $202,000 | +18.1% | 13,378 | +7.7% | 0.00% | – |
| Q4 2013 | $171,000 | -22.3% | 12,420 | +6.5% | 0.00% | – |
| Q3 2013 | $220,000 | – | 11,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |